Date: 2011-11-02
Type of information: Private placement
Company: Genfit (France)
Investors:
Amount: €500,000
Funding type: private placement
Planned used:
Others: Genfit has announced the achievement of a €500,000 private placement reserved to one of its historical shareholders, the University of Lille 2. The operation follows the recent clinical results obtained for GFT505, Genfit’s leading drug candidate, that is currently at the beginning of Phase IIb clinical trials. 156,250 new shares have been issued in connection with this operation. The new shares are assimilated with existing shares immediately after settlement. The capital is made of 13,580,578 shares after the operation.
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Liver diseases
